How does a company with a lead asset cancer drug also get into dermatology? What does blood cancer and keloid scars have in common? The answer is: fibrosis. Fibrosis is another word for scarring. It is the key in the process of healing where connective tissue replaces normal tissue to form scar tissue. It’s how
Read More
The skin is one of the most overlooked, complex and essential organs. It is the body’s first line of defence against dehydration, infection, and injury and plays a role in thermoregulation, vitamin D absorption and the nervous system. Throughout the course of life we are bound to end up with scars from adventures and mishaps,
Read More
Clinical stage pharmaceutical company Pharmaxis (PXS: ASX) is full steam ahead with their Phase 2 clinical trial for flagship drug, PXS-5505. The Company has launched new clinical trial sites in Taiwan in a planned expansion to boost patient recruitment. Designed for use in the treatment of myelofibrosis, a rare blood cancer with a poor prognosis,
Read More
The pharmaceutical industry is an incredibly competitive space with new drug discoveries cropping up all the time, giving hope that we may soon find resolutions to the complicated medical challenges of today. The competitive nature of the space means that whoever is first to market has a clear advantage. Clinical stage pharmaceutical company Pharmaxis (ASX:
Read More